C4 Therapeutics (CCCC) Retained Earnings (2019 - 2025)
Historic Retained Earnings for C4 Therapeutics (CCCC) over the last 7 years, with Q3 2025 value amounting to -$718.2 million.
- C4 Therapeutics' Retained Earnings fell 1987.58% to -$718.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$718.2 million, marking a year-over-year decrease of 1987.58%. This contributed to the annual value of -$633.7 million for FY2024, which is 1993.18% down from last year.
- Per C4 Therapeutics' latest filing, its Retained Earnings stood at -$718.2 million for Q3 2025, which was down 1987.58% from -$686.0 million recorded in Q2 2025.
- In the past 5 years, C4 Therapeutics' Retained Earnings registered a high of -$204.8 million during Q1 2021, and its lowest value of -$718.2 million during Q3 2025.
- Over the past 5 years, C4 Therapeutics' median Retained Earnings value was -$466.6 million (recorded in 2023), while the average stood at -$456.9 million.
- As far as peak fluctuations go, C4 Therapeutics' Retained Earnings plummeted by 5559.04% in 2021, and later tumbled by 1855.02% in 2025.
- Quarter analysis of 5 years shows C4 Therapeutics' Retained Earnings stood at -$267.7 million in 2021, then tumbled by 47.88% to -$395.9 million in 2022, then tumbled by 33.47% to -$528.4 million in 2023, then fell by 19.93% to -$633.7 million in 2024, then fell by 13.34% to -$718.2 million in 2025.
- Its Retained Earnings stands at -$718.2 million for Q3 2025, versus -$686.0 million for Q2 2025 and -$660.0 million for Q1 2025.